Glass fibers in injectable pet medicine triggered a nationwide recall that reached both dogs and horses.
Quick Take
- American Regent, Inc. Animal Health recalled two lots of Adequan Canine and two lots of Adequan i.m. after finding visible glass fiber material in the product.
- The recall covered the consumer level nationwide and involved lots 25011, 3369, 24416, and 25265P.
- The company said it found the fibers during testing of internally retained samples.
- Federal officials said the main risk from particulate matter in an injectable product is irritation, swelling, inflammation, pain, infection, or abscesses.
What the Recall Covers
American Regent, Inc. Animal Health issued the recall on July 31, 2026, and said it applied nationwide to Adequan Canine Injection for dogs and Adequan i.m. Injection for horses.
The company identified the recalled lots as 25011 and 3369 for the canine product, and 24416 and 25265P for the horse product.
‘Glass Fibers’ Found Inside Dog and Horse Medications Prompt Urgent Nationwide Recall https://t.co/DwIWQV0OxB
— People Pets (@PEOPLEPets) August 7, 2026
The recall notice said the problem came from visible glass fiber material found during testing of internally retained samples. That detail matters because it points to a quality-control discovery inside the company’s own sample checks, not a report that started with a pet injury case.
Why the Finding Raised Alarm
The concern is not abstract. The Food and Drug Administration said an intramuscular injectable product that contains particulate matter such as glass fibers may cause local irritation, swelling, inflammation, injection site pain, infection, or abscesses. That is why even a limited lot recall can carry serious weight in veterinary medicine.
At the same time, the public record in this case points to a precautionary action, not a crisis with known injuries. The FDA said American Regent had not received reports of adverse events related to the recalled lots at the time of the recall.
How the Product Moved Through the Market
The distribution trail shows why recalls like this can spread fast. DVM360 reported that the recalled Adequan Canine lots went to online pharmacies, distributors, wholesalers, and veterinary practices across the United States, and the horse-product lots moved through the same channels. That means the affected vials may have reached clinics and customers in many states before the recall announcement.
Pet owners and veterinarians were told to stop using the affected lots immediately. The company also set up customer service and medical information contacts for return, replacement, or credit questions.
What This Recall Says About Drug Safety
This recall fits a familiar pattern in injectable drug quality events. Foreign material recalls are often lot-specific and driven by internal testing before broad harm is reported. That does not make them routine in the everyday sense, but it does show how drug makers and regulators try to act before a bad batch causes injuries.
The bigger lesson is simple. Injectable products leave little room for error, because even tiny contaminants can turn a routine treatment into a vet visit that goes off course.
A glass fiber is not a small paperwork problem; in a syringe, it is exactly the kind of thing quality systems are built to catch before an animal pays the price.
For horse and dog owners, the practical takeaway is to check lot numbers, stop using any recalled vials, and call a veterinarian if an animal has been given an affected product. In recalls like this, speed matters more than debate, because the safest move is to get the suspect medicine out of circulation first and sort out the rest later.
Sources:
foxbusiness.com, people.com, usatoday.com, facebook.com
